eligibility_summary
Eligibility: adults 18–75 with WHO-confirmed ocular adnexal MALT lymphoma (pathology, immunophenotype, genetics), TNM T1–T3, consent. Exclude: T4, prior lymphoma therapy, cataract needing surgery/impairing tests or VA<20/40, need other ocular surgery, significant ocular disease (corneal disease/infection, ICE, dysgenesis, microphthalmos, uveitis, glaucoma, trauma, RVO/RAO, detachment), long-term steroids, other trials, pregnant/lactating, serious illness, unable to consent. If both eyes eligible, right eye enrolled only.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06064344, multicenter non-inferiority RCT in primary ocular adnexal MALT lymphoma (T1–3). Interventions: (1) Intralesional rituximab—type: chimeric anti-CD20 monoclonal antibody (biologic). Mechanism: binds CD20 on B cells, causing B‑cell depletion via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis, local injection concentrates effect at the lesion. (2) Involved Site Radiation Therapy (ISRT)—type: localized external beam radiation. Mechanism: induces DNA double-strand breaks and ROS, triggering cell-cycle arrest and apoptosis in tumor cells. Targets: neoplastic marginal zone B cells in the ocular adnexa (CD20+). Pathways: CD20 surface antigen and immune effector pathways (FcγR/complement) for rituximab, DNA damage response/apoptosis pathways for radiation.